Director/PDMR Shareholding

GSK PLC
16 July 2024
 

GSK plc (the 'Company')

Transaction notification


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Emma Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£15.0500

789



£15.0500

1,311



£15.0500

1,482

 






d)

Aggregated information

 


 

Aggregated volume Price

 

3,582

£15.0500

e)

Date of the transaction

2024-07-15

f)

Place of the transaction

 

London Stock Exchange (XLON)


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Hal Barron

b)

Position/status

Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W2044

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 11 July 2024 on ADSs held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$38.9000

429










d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

 

e)

Date of the transaction

2024-07-15

f)

Place of the transaction

 

New York Stock Exchange (XNYS)


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Julie Brown

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£15.0500

565






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2024-07-15

f)

Place of the transaction

 

London Stock Exchange (XLON)


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Diana Conrad

b)

Position/status

Chief People Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£15.0500

123



£15.0500

238



£15.0500

373






d)

Aggregated information

 


 

Aggregated volume Price

 

734

£15.0500

e)

Date of the transaction

2024-07-15

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£15.0500

152



£15.0500

232



£15.0500

378






d)

Aggregated information

 


 

Aggregated volume Price

 

762

£15.0500

e)

Date of the transaction

2024-07-15

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sally Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£15.0500

71



£15.0500

144



£15.0500

234






d)

Aggregated information

 


 

Aggregated volume Price

 

449

£15.0500

e)

Date of the transaction

2024-07-15

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Luke Miels

b)

Position/status

Chief Commercial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£15.0500

259



£15.0500

559



£15.0500

704






d)

Aggregated information

 


 

Aggregated volume Price

 

1,522

£15.0500

e)

Date of the transaction

2024-07-15

f)

Place of the transaction

 

London Stock Exchange (XLON)


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Shobie Ramakrishnan

b)

Position/status

Chief Digital and Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W2044

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 11 July 2024 on ADSs held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$38.9000

26



$38.9000

113



$38.9000

175






d)

Aggregated information

 


 

Aggregated volume Price

 

314

$38.9000

e)

Date of the transaction

2024-07-15

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

President Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£15.0500

172



£15.0500

323



£15.0500

448






d)

Aggregated information

 


 

Aggregated volume Price

 

943

£15.0500

e)

Date of the transaction

2024-07-15

f)

Place of the transaction

 

London Stock Exchange (XLON)


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£15.0500

156



£15.0500

259



£15.0500

539






d)

Aggregated information

 


 

Aggregated volume Price

 

954

£15.0500

e)

Date of the transaction

2024-07-15

f)

Place of the transaction

 

London Stock Exchange (XLON)


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Philip Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£15.0500

108



£15.0500

169



£15.0500

301






d)

Aggregated information

 

 


Aggregated volume Price

578

£15.0500

e)

Date of the transaction

2024-07-15

f)

Place of the transaction

 

London Stock Exchange (XLON)


 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, Global Health, GSK

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£15.0500

114



£15.0500

413



£15.0500

466






d)

Aggregated information

 


 

Aggregated volume Price

 

993

£15.0500

e)

Date of the transaction

2024-07-15

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Tony Wood

b)

Position/status

Chief Scientific Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

 

 

 

 


Price(s)

Volume(s)



£15.0500

196

 

 

 

 


£15.0500

575




 

 

 


d)

Aggregated information

 


 

Aggregated volume Price

 

771

£15.0500

e)

Date of the transaction

2024-07-15

f)

Place of the transaction

 

London Stock Exchange (XLON)


 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Emma Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024 on Ordinary Shares held in the Company's Performance Share Plan subject to a 2-year holding period

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.0500

7033.460

 

 

 

d)

Aggregated information

Aggregated volume Price

N/A (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2024-07-15

f)

Place of the transaction

 

London Stock Exchange (XLON)


 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

President Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024, on Ordinary Shares held within an ISA

 

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£15.2522

19






d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price


e)

Date of the transaction

2024-07-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

  

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Victoria Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2024, on Ordinary Shares held within an ISA

 

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£15.2522

16






d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price


e)

Date of the transaction

2024-07-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

GSK (GSK)
UK 100

Latest directors dealings